A Phase I, Randomized, Open-Label, Three-period, Three-Treatment Crossover Study Comparing the Bioavailability and Absorption of Two Methylphenidate Extended-Release Orally Disintegrating Tablets With a Reference Extended-Release Formulation of Methylphenidate in Healthy Adults under Fasted Conditions

Trial Profile

A Phase I, Randomized, Open-Label, Three-period, Three-Treatment Crossover Study Comparing the Bioavailability and Absorption of Two Methylphenidate Extended-Release Orally Disintegrating Tablets With a Reference Extended-Release Formulation of Methylphenidate in Healthy Adults under Fasted Conditions

Completed
Phase of Trial: Phase I

Latest Information Update: 25 May 2017

At a glance

  • Drugs Methylphenidate (Primary) ; Methylphenidate
  • Indications Attention-deficit hyperactivity disorder
  • Focus Pharmacokinetics; Proof of concept
  • Sponsors Neos Therapeutics
  • Most Recent Events

    • 29 Jun 2015 New trial record
    • 24 Jun 2015 Results published in a Neos Therapeutics Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top